Chris Gibson describes the new technologies that are accelerating and refining drug development.

George Simeon explains how the 876-participant study showed non-inferiority vs Shingrix and lower rates of solicited local and SAEs.

Vipin Garg explains the theory of how GLP-1 cause weight loss and gives the rationale for adding glucagon agonism for added effect.

Harvey Berger describes the science of ferroptosis and his experience working with Kojin's scientific founder Stuart Schreiber.

Ken Keller describes recent advances in ADC technology, talks about the recent Merck deal, and what it was like to change breast cancer.

Bobby Azamian provides an update on the commercial launch of XDEMY in demodex blepharitis, and discusses additional programs.

John Oyler discusses BeiGene's BTK, PD1, and other programs, and talks about the company's cost structure.

Bill Sibold describes how resmetirom acts on fibrosis and could be the first commercial product in NASH.

Paul Stoffels describes how his company's decentralized CAR-T process is designed to have a shorter 'brain-to-vein' time.

Yvonne Greenstreet talks about how Alnylam has been moving RNAi beyond the liver and previews the year ahead, including HELIOS-B.

Tim Van Hauwermeiren describes the science behind argenx's success, the potential market potential, pipeline programs, and Europe.

Jason Coloma shares the smaller company's perspective of how a licensing deal was scuttled by the FTC.

The founder and CEO of PureTech talks about Karuna, and PureTech's business model of having a wholly owned pipeline plus founded entities.

Patrick Nosker gives his take on today's conference news and highlights the science behind some of his firm's top holdings.

Bahija Jallal talks about the experience Immunocore has gained commercializing KIMMTRAK since its 2022 approval.

Takeda's CEO talks about the $4B+ Nimbus acquisition, recent approvals, and what's ahead for the company in 2024.

Noubar Afeyan hits on themes like partnering with pharma in earlier stages, AI, and the globalization of biotech.

Brian Skorney comments on the Ambrx and Harpoon acquisitions, the year ahead in biotech, and his top picks Biogen, Neurocrine, and Biohaven.

He discusses protein degradation, KV7 ion channel modulation, myostatin inhibition for obesity, and more.

Sek Kathiresan discusses Verve's first-in-human data, getting an IND cleared in the United States, and the company's partnership with Lilly.